| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Testosterone | 117 | 2024 | 2494 | 15.120 |
Why?
|
| Androgens | 58 | 2023 | 1279 | 10.070 |
Why?
|
| Androgen Antagonists | 33 | 2024 | 1411 | 6.080 |
Why?
|
| Hormone Replacement Therapy | 37 | 2023 | 753 | 5.600 |
Why?
|
| Hypogonadism | 27 | 2023 | 801 | 5.130 |
Why?
|
| Prostatic Neoplasms | 38 | 2024 | 11083 | 2.460 |
Why?
|
| Muscle Strength | 14 | 2019 | 637 | 2.250 |
Why?
|
| Mobility Limitation | 13 | 2020 | 408 | 2.210 |
Why?
|
| Sex Hormone-Binding Globulin | 23 | 2022 | 558 | 2.070 |
Why?
|
| Body Composition | 23 | 2024 | 2439 | 1.800 |
Why?
|
| Insulin Resistance | 15 | 2024 | 3985 | 1.560 |
Why?
|
| Antineoplastic Agents, Hormonal | 11 | 2023 | 1534 | 1.470 |
Why?
|
| Finasteride | 4 | 2022 | 86 | 1.370 |
Why?
|
| Double-Blind Method | 43 | 2023 | 12437 | 1.330 |
Why?
|
| Aromatase Inhibitors | 4 | 2017 | 518 | 1.290 |
Why?
|
| Isoflavones | 4 | 2010 | 139 | 1.230 |
Why?
|
| Estradiol | 19 | 2017 | 1947 | 1.180 |
Why?
|
| 5-alpha Reductase Inhibitors | 5 | 2022 | 114 | 1.170 |
Why?
|
| Anabolic Agents | 6 | 2018 | 256 | 1.160 |
Why?
|
| Aging | 27 | 2023 | 8731 | 1.130 |
Why?
|
| Performance-Enhancing Substances | 2 | 2018 | 31 | 1.120 |
Why?
|
| Administration, Cutaneous | 13 | 2020 | 715 | 1.110 |
Why?
|
| Eunuchism | 2 | 2017 | 19 | 1.070 |
Why?
|
| Sexual Dysfunction, Physiological | 8 | 2022 | 363 | 1.040 |
Why?
|
| Cardiovascular Diseases | 26 | 2023 | 15652 | 1.020 |
Why?
|
| Hysterectomy | 4 | 2019 | 864 | 0.940 |
Why?
|
| Graves Disease | 6 | 2004 | 241 | 0.930 |
Why?
|
| Dietary Proteins | 3 | 2021 | 959 | 0.920 |
Why?
|
| Estrone | 5 | 2017 | 234 | 0.900 |
Why?
|
| Male | 173 | 2024 | 363698 | 0.870 |
Why?
|
| Alopecia | 4 | 2022 | 414 | 0.870 |
Why?
|
| Erectile Dysfunction | 8 | 2017 | 437 | 0.860 |
Why?
|
| Receptors, Androgen | 4 | 2024 | 1088 | 0.850 |
Why?
|
| Erythropoiesis | 3 | 2018 | 691 | 0.790 |
Why?
|
| Muscle, Skeletal | 10 | 2024 | 4958 | 0.740 |
Why?
|
| Men's Health | 3 | 2019 | 75 | 0.740 |
Why?
|
| Sex Reassignment Procedures | 1 | 2022 | 72 | 0.730 |
Why?
|
| Gels | 11 | 2023 | 419 | 0.730 |
Why?
|
| Chorionic Gonadotropin | 1 | 2023 | 457 | 0.710 |
Why?
|
| Analgesics, Opioid | 5 | 2017 | 3835 | 0.710 |
Why?
|
| Humans | 225 | 2024 | 765968 | 0.700 |
Why?
|
| Thyroid Gland | 8 | 2005 | 1180 | 0.700 |
Why?
|
| Choristoma | 5 | 2004 | 206 | 0.690 |
Why?
|
| Testis | 4 | 2022 | 780 | 0.660 |
Why?
|
| Aged | 108 | 2024 | 171117 | 0.660 |
Why?
|
| Hypothyroidism | 6 | 2005 | 667 | 0.650 |
Why?
|
| 3-Oxo-5-alpha-Steroid 4-Dehydrogenase | 2 | 2017 | 75 | 0.650 |
Why?
|
| Lipoproteins | 4 | 2019 | 866 | 0.630 |
Why?
|
| Leuprolide | 4 | 2018 | 312 | 0.610 |
Why?
|
| Phosphodiesterase 5 Inhibitors | 3 | 2013 | 103 | 0.600 |
Why?
|
| Middle Aged | 93 | 2024 | 223009 | 0.590 |
Why?
|
| Gonadal Steroid Hormones | 8 | 2017 | 705 | 0.590 |
Why?
|
| Erythropoietin | 3 | 2018 | 716 | 0.580 |
Why?
|
| Agrin | 1 | 2017 | 75 | 0.560 |
Why?
|
| Prostate | 5 | 2024 | 1755 | 0.550 |
Why?
|
| Fatty Acid-Binding Proteins | 1 | 2018 | 291 | 0.530 |
Why?
|
| Drugs, Investigational | 3 | 2007 | 211 | 0.530 |
Why?
|
| Sulfones | 3 | 2013 | 447 | 0.530 |
Why?
|
| Gonadotrophs | 1 | 2016 | 19 | 0.520 |
Why?
|
| Pain Perception | 1 | 2017 | 198 | 0.510 |
Why?
|
| Blood Glucose | 9 | 2021 | 6424 | 0.500 |
Why?
|
| Postmenopause | 7 | 2014 | 2515 | 0.490 |
Why?
|
| Sarcopenia | 2 | 2017 | 378 | 0.490 |
Why?
|
| Quality of Life | 13 | 2022 | 13462 | 0.480 |
Why?
|
| Soybean Proteins | 3 | 2010 | 55 | 0.480 |
Why?
|
| Sexual Dysfunctions, Psychological | 1 | 2016 | 193 | 0.470 |
Why?
|
| Doping in Sports | 2 | 2018 | 63 | 0.470 |
Why?
|
| Thromboembolism | 2 | 2018 | 1003 | 0.460 |
Why?
|
| Nitriles | 3 | 2016 | 982 | 0.460 |
Why?
|
| Randomized Controlled Trials as Topic | 6 | 2020 | 10383 | 0.440 |
Why?
|
| Orchiectomy | 2 | 2015 | 460 | 0.440 |
Why?
|
| Reproduction | 2 | 2023 | 641 | 0.430 |
Why?
|
| Triazoles | 2 | 2016 | 897 | 0.430 |
Why?
|
| Catastrophization | 1 | 2017 | 352 | 0.430 |
Why?
|
| Hypopituitarism | 3 | 2014 | 254 | 0.430 |
Why?
|
| Gonadotropin-Releasing Hormone | 4 | 2018 | 1133 | 0.430 |
Why?
|
| Luteinizing Hormone | 6 | 2018 | 826 | 0.430 |
Why?
|
| Oxygen Consumption | 2 | 2018 | 1870 | 0.420 |
Why?
|
| Steroids | 2 | 2017 | 933 | 0.420 |
Why?
|
| Liver | 4 | 2024 | 7562 | 0.420 |
Why?
|
| Athletes | 2 | 2018 | 1162 | 0.410 |
Why?
|
| Cognition | 5 | 2017 | 7049 | 0.410 |
Why?
|
| Dyslipidemias | 2 | 2018 | 869 | 0.410 |
Why?
|
| Activities of Daily Living | 2 | 2021 | 2415 | 0.400 |
Why?
|
| Adrenal Gland Neoplasms | 2 | 2010 | 730 | 0.400 |
Why?
|
| Thyroxine | 7 | 2004 | 672 | 0.400 |
Why?
|
| Bone Density | 9 | 2022 | 3491 | 0.400 |
Why?
|
| Azasteroids | 1 | 2012 | 37 | 0.390 |
Why?
|
| Atherosclerosis | 5 | 2019 | 3424 | 0.390 |
Why?
|
| Substance-Related Disorders | 2 | 2024 | 4416 | 0.390 |
Why?
|
| Human Growth Hormone | 1 | 2017 | 638 | 0.380 |
Why?
|
| Voice | 1 | 2015 | 268 | 0.380 |
Why?
|
| Thyrotoxicosis | 2 | 2002 | 85 | 0.380 |
Why?
|
| Glucose | 3 | 2019 | 4335 | 0.370 |
Why?
|
| Spleen | 1 | 2017 | 2296 | 0.370 |
Why?
|
| Andropause | 2 | 2013 | 8 | 0.360 |
Why?
|
| Adult | 53 | 2021 | 223044 | 0.350 |
Why?
|
| Insulin | 11 | 2019 | 6599 | 0.340 |
Why?
|
| Tongue Diseases | 2 | 2001 | 70 | 0.340 |
Why?
|
| Insulin-Like Growth Factor I | 7 | 2023 | 1936 | 0.340 |
Why?
|
| Aged, 80 and over | 38 | 2023 | 59489 | 0.340 |
Why?
|
| Dosage Forms | 1 | 2009 | 55 | 0.340 |
Why?
|
| Treatment Outcome | 29 | 2021 | 65188 | 0.330 |
Why?
|
| Inflammation | 10 | 2016 | 10850 | 0.320 |
Why?
|
| Thyroiditis, Suppurative | 2 | 2006 | 7 | 0.320 |
Why?
|
| Dose-Response Relationship, Drug | 9 | 2019 | 10729 | 0.320 |
Why?
|
| Health Status | 4 | 2018 | 4080 | 0.320 |
Why?
|
| Blood Viscosity | 2 | 2015 | 125 | 0.310 |
Why?
|
| Virilism | 2 | 2005 | 28 | 0.310 |
Why?
|
| Accidental Falls | 4 | 2020 | 1078 | 0.310 |
Why?
|
| Piperazines | 3 | 2013 | 2549 | 0.300 |
Why?
|
| Streptococcal Infections | 2 | 2006 | 617 | 0.300 |
Why?
|
| Thyroid Neoplasms | 6 | 2005 | 2371 | 0.290 |
Why?
|
| Pheochromocytoma | 1 | 2010 | 323 | 0.290 |
Why?
|
| Independent Living | 7 | 2022 | 585 | 0.290 |
Why?
|
| Placebos | 7 | 2018 | 1659 | 0.280 |
Why?
|
| Polycythemia | 3 | 2013 | 125 | 0.280 |
Why?
|
| Autoantibodies | 1 | 2016 | 2113 | 0.280 |
Why?
|
| Hormones | 5 | 2014 | 863 | 0.270 |
Why?
|
| Substance Abuse Detection | 1 | 2010 | 301 | 0.270 |
Why?
|
| Viridans Streptococci | 1 | 2006 | 16 | 0.270 |
Why?
|
| Peptostreptococcus | 1 | 2006 | 27 | 0.270 |
Why?
|
| Executive Function | 2 | 2017 | 1391 | 0.270 |
Why?
|
| Lipids | 5 | 2018 | 3315 | 0.270 |
Why?
|
| Cytokines | 4 | 2018 | 7421 | 0.270 |
Why?
|
| Bone Diseases, Endocrine | 1 | 2006 | 2 | 0.270 |
Why?
|
| Antithyroid Agents | 2 | 2003 | 72 | 0.260 |
Why?
|
| Osteoporosis | 3 | 2010 | 1582 | 0.260 |
Why?
|
| Metabolic Diseases | 2 | 2014 | 687 | 0.260 |
Why?
|
| Risk Factors | 24 | 2020 | 74840 | 0.260 |
Why?
|
| Myelolipoma | 1 | 2006 | 14 | 0.260 |
Why?
|
| Hyperglycemia | 4 | 2008 | 1393 | 0.250 |
Why?
|
| Osteitis Deformans | 2 | 2003 | 54 | 0.250 |
Why?
|
| Luteoma | 1 | 2005 | 3 | 0.250 |
Why?
|
| Heart | 1 | 2019 | 4414 | 0.250 |
Why?
|
| Dihydrotestosterone | 3 | 2013 | 193 | 0.250 |
Why?
|
| Exercise Test | 5 | 2020 | 2180 | 0.250 |
Why?
|
| Absorptiometry, Photon | 4 | 2021 | 1707 | 0.240 |
Why?
|
| Fatigue | 3 | 2018 | 1549 | 0.240 |
Why?
|
| Parathyroid Neoplasms | 1 | 2006 | 244 | 0.240 |
Why?
|
| Peptide Fragments | 1 | 2017 | 5125 | 0.240 |
Why?
|
| Prostatectomy | 2 | 2024 | 1782 | 0.240 |
Why?
|
| Hyperlipidemias | 3 | 2010 | 770 | 0.230 |
Why?
|
| Thyrotropin | 3 | 2004 | 841 | 0.230 |
Why?
|
| Walking | 4 | 2018 | 1198 | 0.230 |
Why?
|
| Estrogens | 3 | 2012 | 1529 | 0.230 |
Why?
|
| Nonsteroidal Anti-Androgens | 1 | 2024 | 9 | 0.230 |
Why?
|
| Sexual Behavior | 5 | 2016 | 2193 | 0.230 |
Why?
|
| Tomography, Spiral Computed | 1 | 2006 | 273 | 0.230 |
Why?
|
| Ovariectomy | 3 | 2015 | 611 | 0.230 |
Why?
|
| Endocrine System Diseases | 1 | 2006 | 243 | 0.220 |
Why?
|
| Flushing | 1 | 2004 | 52 | 0.220 |
Why?
|
| Adipose Tissue | 2 | 2013 | 3312 | 0.220 |
Why?
|
| Young Adult | 16 | 2021 | 59889 | 0.220 |
Why?
|
| Pituitary Neoplasms | 2 | 2004 | 1321 | 0.220 |
Why?
|
| Methimazole | 1 | 2003 | 41 | 0.220 |
Why?
|
| Necrobiosis Lipoidica | 1 | 2003 | 14 | 0.220 |
Why?
|
| Goiter | 1 | 2004 | 86 | 0.220 |
Why?
|
| Carcinoma, Papillary | 3 | 2005 | 788 | 0.220 |
Why?
|
| Amiodarone | 1 | 2005 | 216 | 0.220 |
Why?
|
| Depression | 5 | 2021 | 8237 | 0.220 |
Why?
|
| Amyloidosis | 2 | 2003 | 885 | 0.220 |
Why?
|
| Hypercalcemia | 1 | 2006 | 426 | 0.220 |
Why?
|
| Mental Health | 1 | 2018 | 3278 | 0.220 |
Why?
|
| Pentoxifylline | 1 | 2003 | 54 | 0.210 |
Why?
|
| Androgen Receptor Antagonists | 1 | 2024 | 123 | 0.210 |
Why?
|
| Menopause, Premature | 2 | 2019 | 124 | 0.210 |
Why?
|
| Hematologic Agents | 1 | 2003 | 38 | 0.210 |
Why?
|
| Affect | 3 | 2018 | 1500 | 0.210 |
Why?
|
| Female | 55 | 2022 | 396112 | 0.210 |
Why?
|
| Syncope | 1 | 2006 | 429 | 0.210 |
Why?
|
| Methyltestosterone | 1 | 2002 | 19 | 0.200 |
Why?
|
| Alkaline Phosphatase | 2 | 2003 | 854 | 0.200 |
Why?
|
| Carcinoma | 2 | 2006 | 2312 | 0.200 |
Why?
|
| Hepatitis C | 2 | 2022 | 1597 | 0.200 |
Why?
|
| Metabolism | 2 | 2016 | 193 | 0.200 |
Why?
|
| Transsexualism | 1 | 2006 | 210 | 0.190 |
Why?
|
| Testosterone Congeners | 1 | 2002 | 62 | 0.190 |
Why?
|
| Adiposity | 1 | 2012 | 1890 | 0.190 |
Why?
|
| Musculoskeletal System | 1 | 2024 | 187 | 0.190 |
Why?
|
| Kidney | 1 | 2017 | 7066 | 0.190 |
Why?
|
| Vitiligo | 1 | 2002 | 96 | 0.190 |
Why?
|
| Injections, Intramuscular | 2 | 2022 | 552 | 0.190 |
Why?
|
| Coronary Vessels | 3 | 2019 | 3096 | 0.190 |
Why?
|
| Organ Size | 2 | 2017 | 2260 | 0.190 |
Why?
|
| Interleukins | 1 | 2006 | 791 | 0.180 |
Why?
|
| Adipokines | 2 | 2016 | 308 | 0.180 |
Why?
|
| Triiodothyronine | 1 | 2003 | 496 | 0.180 |
Why?
|
| Anti-Arrhythmia Agents | 1 | 2005 | 769 | 0.180 |
Why?
|
| Toxoplasmosis, Cerebral | 1 | 2000 | 19 | 0.180 |
Why?
|
| Pituitary Apoplexy | 1 | 2001 | 29 | 0.180 |
Why?
|
| Thyroidectomy | 2 | 2004 | 916 | 0.180 |
Why?
|
| Wounds, Stab | 1 | 2001 | 71 | 0.180 |
Why?
|
| Tuberculosis, Gastrointestinal | 1 | 2000 | 20 | 0.180 |
Why?
|
| Prospective Studies | 8 | 2024 | 54802 | 0.180 |
Why?
|
| Vascular Fistula | 1 | 2001 | 50 | 0.180 |
Why?
|
| Thyroid Nodule | 3 | 2005 | 779 | 0.180 |
Why?
|
| Hepatic Veins | 1 | 2001 | 112 | 0.180 |
Why?
|
| Self Administration | 1 | 2022 | 385 | 0.180 |
Why?
|
| Pituitary Gland | 1 | 2003 | 631 | 0.180 |
Why?
|
| Renal Artery Obstruction | 1 | 2002 | 218 | 0.180 |
Why?
|
| Drug Users | 1 | 2022 | 134 | 0.180 |
Why?
|
| Doxycycline | 1 | 2002 | 349 | 0.170 |
Why?
|
| Tuberculoma | 1 | 2000 | 13 | 0.170 |
Why?
|
| Cross-Sectional Studies | 17 | 2022 | 26318 | 0.170 |
Why?
|
| Radionuclide Imaging | 5 | 2003 | 1978 | 0.170 |
Why?
|
| Injections, Subcutaneous | 1 | 2022 | 682 | 0.170 |
Why?
|
| AIDS-Related Opportunistic Infections | 2 | 2001 | 664 | 0.170 |
Why?
|
| Libido | 5 | 2016 | 123 | 0.170 |
Why?
|
| Organ Specificity | 2 | 2017 | 1965 | 0.170 |
Why?
|
| Orgasm | 2 | 2017 | 63 | 0.170 |
Why?
|
| Body Mass Index | 11 | 2017 | 13039 | 0.170 |
Why?
|
| Diabetes Complications | 2 | 2012 | 1316 | 0.170 |
Why?
|
| Leydig Cells | 1 | 1999 | 55 | 0.160 |
Why?
|
| Penile Erection | 2 | 2017 | 100 | 0.160 |
Why?
|
| Polycystic Kidney, Autosomal Dominant | 1 | 2000 | 166 | 0.160 |
Why?
|
| Energy Intake | 2 | 2017 | 2141 | 0.160 |
Why?
|
| Blood Platelets | 2 | 2020 | 2464 | 0.160 |
Why?
|
| Mediastinal Diseases | 1 | 1999 | 91 | 0.160 |
Why?
|
| Nurse's Role | 1 | 2020 | 187 | 0.160 |
Why?
|
| Sexuality | 2 | 2014 | 180 | 0.160 |
Why?
|
| Pulmonary Edema | 1 | 2002 | 412 | 0.160 |
Why?
|
| Prostate-Specific Antigen | 4 | 2021 | 2464 | 0.160 |
Why?
|
| Purpura | 1 | 1999 | 115 | 0.160 |
Why?
|
| Colonic Diseases | 1 | 2000 | 204 | 0.160 |
Why?
|
| Carcinoid Tumor | 1 | 2000 | 225 | 0.160 |
Why?
|
| Family Planning Services | 1 | 2002 | 278 | 0.150 |
Why?
|
| Depressive Disorder, Major | 1 | 2016 | 4808 | 0.150 |
Why?
|
| Interferon-alpha | 1 | 2003 | 910 | 0.150 |
Why?
|
| Skull | 1 | 2003 | 811 | 0.150 |
Why?
|
| Pulmonary Embolism | 2 | 2006 | 2598 | 0.150 |
Why?
|
| Pelvic Floor | 1 | 2019 | 138 | 0.150 |
Why?
|
| Magnetic Resonance Imaging | 10 | 2019 | 36532 | 0.150 |
Why?
|
| Erythrocyte Count | 1 | 2018 | 158 | 0.150 |
Why?
|
| Safety Management | 1 | 2004 | 763 | 0.150 |
Why?
|
| Estrogen Replacement Therapy | 3 | 2015 | 1206 | 0.150 |
Why?
|
| Obesity | 7 | 2022 | 13076 | 0.150 |
Why?
|
| Myocardial Infarction | 2 | 2023 | 11499 | 0.150 |
Why?
|
| Motor Activity | 3 | 2014 | 2704 | 0.150 |
Why?
|
| Portal Vein | 1 | 2001 | 435 | 0.150 |
Why?
|
| Prostatism | 2 | 2008 | 16 | 0.150 |
Why?
|
| Iodine Radioisotopes | 4 | 2003 | 1029 | 0.140 |
Why?
|
| Anemia | 3 | 2017 | 1511 | 0.140 |
Why?
|
| Eyelid Diseases | 1 | 1999 | 155 | 0.140 |
Why?
|
| Urolithiasis | 1 | 2019 | 123 | 0.140 |
Why?
|
| Neoplasm Metastasis | 3 | 2023 | 4893 | 0.140 |
Why?
|
| Drug Administration Routes | 3 | 2017 | 152 | 0.140 |
Why?
|
| Inflammation Mediators | 4 | 2018 | 1884 | 0.140 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2012 | 4058 | 0.140 |
Why?
|
| Cohort Studies | 8 | 2023 | 41649 | 0.140 |
Why?
|
| Ventricular Outflow Obstruction | 1 | 1999 | 262 | 0.140 |
Why?
|
| Population Dynamics | 1 | 2019 | 314 | 0.140 |
Why?
|
| Patient Care Management | 1 | 2020 | 303 | 0.140 |
Why?
|
| Stroke | 2 | 2023 | 9747 | 0.140 |
Why?
|
| Drug Approval | 1 | 2024 | 818 | 0.140 |
Why?
|
| Liver Abscess | 1 | 1997 | 81 | 0.140 |
Why?
|
| Cardiac Output | 1 | 2019 | 840 | 0.140 |
Why?
|
| Endothelium | 1 | 2019 | 767 | 0.130 |
Why?
|
| Lymphoma, B-Cell | 1 | 2003 | 943 | 0.130 |
Why?
|
| Hemoglobins | 4 | 2017 | 1530 | 0.130 |
Why?
|
| Coronary Disease | 3 | 2014 | 5912 | 0.130 |
Why?
|
| Heart Septal Defects, Ventricular | 1 | 1999 | 477 | 0.130 |
Why?
|
| Prolactin | 1 | 2018 | 625 | 0.130 |
Why?
|
| Physical Fitness | 2 | 2020 | 742 | 0.130 |
Why?
|
| Vascular Resistance | 1 | 2019 | 941 | 0.130 |
Why?
|
| Athletic Performance | 1 | 2017 | 112 | 0.130 |
Why?
|
| Methotrexate | 1 | 2023 | 1722 | 0.130 |
Why?
|
| Sleep Apnea Syndromes | 2 | 2015 | 969 | 0.130 |
Why?
|
| Counseling | 1 | 2004 | 1551 | 0.130 |
Why?
|
| Intra-Abdominal Fat | 1 | 2021 | 623 | 0.130 |
Why?
|
| C-Reactive Protein | 5 | 2016 | 3850 | 0.130 |
Why?
|
| Clinical Trials as Topic | 4 | 2024 | 8041 | 0.130 |
Why?
|
| Ferritins | 1 | 2018 | 600 | 0.130 |
Why?
|
| Acanthosis Nigricans | 1 | 2015 | 49 | 0.120 |
Why?
|
| Adenoma | 2 | 2003 | 2152 | 0.120 |
Why?
|
| Ejaculation | 1 | 2015 | 59 | 0.120 |
Why?
|
| Diabetes Mellitus | 5 | 2013 | 5891 | 0.120 |
Why?
|
| Glucose Tolerance Test | 1 | 2018 | 1180 | 0.120 |
Why?
|
| Hypoglycemia | 1 | 2002 | 896 | 0.120 |
Why?
|
| Italy | 8 | 2010 | 854 | 0.120 |
Why?
|
| Erythrocyte Deformability | 1 | 2015 | 54 | 0.120 |
Why?
|
| Mexico | 1 | 2017 | 777 | 0.120 |
Why?
|
| Hypertension | 5 | 2015 | 8626 | 0.120 |
Why?
|
| Dementia | 2 | 2019 | 2744 | 0.120 |
Why?
|
| Sound Spectrography | 1 | 2015 | 114 | 0.120 |
Why?
|
| Abdominal Fat | 1 | 2016 | 217 | 0.120 |
Why?
|
| Administration, Oral | 2 | 2013 | 4015 | 0.120 |
Why?
|
| Patient Selection | 4 | 2015 | 4255 | 0.120 |
Why?
|
| Case-Control Studies | 6 | 2021 | 22223 | 0.110 |
Why?
|
| Fibrinogen | 2 | 2012 | 895 | 0.110 |
Why?
|
| Meta-Analysis as Topic | 1 | 2019 | 1370 | 0.110 |
Why?
|
| Behavior | 1 | 2017 | 535 | 0.110 |
Why?
|
| Drug Monitoring | 4 | 2017 | 962 | 0.110 |
Why?
|
| Cardiovascular System | 1 | 2021 | 841 | 0.110 |
Why?
|
| Exercise Tolerance | 1 | 2019 | 841 | 0.110 |
Why?
|
| Spinal Neoplasms | 1 | 2000 | 708 | 0.110 |
Why?
|
| Patients | 1 | 2020 | 910 | 0.110 |
Why?
|
| Tuberculosis, Pulmonary | 1 | 2000 | 838 | 0.110 |
Why?
|
| Anthropometry | 1 | 2018 | 1338 | 0.110 |
Why?
|
| Patient Education as Topic | 1 | 2004 | 2334 | 0.110 |
Why?
|
| Electrocardiography | 2 | 2017 | 6404 | 0.110 |
Why?
|
| Follicle Stimulating Hormone | 1 | 2016 | 731 | 0.110 |
Why?
|
| Receptors, Interleukin-6 | 2 | 2005 | 226 | 0.110 |
Why?
|
| Neuropsychological Tests | 2 | 2017 | 7123 | 0.110 |
Why?
|
| Disease Progression | 4 | 2019 | 13632 | 0.110 |
Why?
|
| Androstenedione | 1 | 2013 | 138 | 0.110 |
Why?
|
| Frail Elderly | 2 | 2012 | 785 | 0.110 |
Why?
|
| Hair | 1 | 2017 | 508 | 0.110 |
Why?
|
| Practice Guidelines as Topic | 2 | 2014 | 7425 | 0.110 |
Why?
|
| Tomography, X-Ray Computed | 10 | 2017 | 20659 | 0.110 |
Why?
|
| Ventricular Dysfunction, Right | 1 | 1999 | 645 | 0.110 |
Why?
|
| Pain Threshold | 1 | 2017 | 604 | 0.110 |
Why?
|
| Pelvis | 1 | 2018 | 738 | 0.110 |
Why?
|
| Tablets | 1 | 2013 | 149 | 0.110 |
Why?
|
| Gastrointestinal Hemorrhage | 1 | 2000 | 1127 | 0.100 |
Why?
|
| Risk Assessment | 9 | 2020 | 24282 | 0.100 |
Why?
|
| Aorta, Abdominal | 1 | 2016 | 596 | 0.100 |
Why?
|
| Purines | 2 | 2013 | 615 | 0.100 |
Why?
|
| Fractures, Bone | 2 | 2022 | 2041 | 0.100 |
Why?
|
| Diagnosis, Differential | 7 | 2005 | 12976 | 0.100 |
Why?
|
| Anticholesteremic Agents | 1 | 2000 | 970 | 0.100 |
Why?
|
| Calcinosis | 1 | 2001 | 1479 | 0.100 |
Why?
|
| Sebum | 1 | 2012 | 17 | 0.100 |
Why?
|
| Patient Satisfaction | 2 | 2015 | 3475 | 0.100 |
Why?
|
| Canada | 1 | 2017 | 2119 | 0.100 |
Why?
|
| Cholesterol | 2 | 2016 | 2898 | 0.090 |
Why?
|
| Interleukin-6 | 6 | 2012 | 3222 | 0.090 |
Why?
|
| Neurosecretory Systems | 1 | 2013 | 222 | 0.090 |
Why?
|
| Chromatography, Liquid | 2 | 2012 | 990 | 0.090 |
Why?
|
| Voice Disorders | 1 | 2015 | 286 | 0.090 |
Why?
|
| Lumbar Vertebrae | 2 | 2017 | 1873 | 0.090 |
Why?
|
| Neoplasms, Hormone-Dependent | 1 | 2014 | 409 | 0.090 |
Why?
|
| Tandem Mass Spectrometry | 3 | 2012 | 1192 | 0.090 |
Why?
|
| Plasminogen Activator Inhibitor 1 | 1 | 2012 | 282 | 0.090 |
Why?
|
| Lipid Metabolism | 1 | 2019 | 1892 | 0.090 |
Why?
|
| Vasodilation | 1 | 2015 | 970 | 0.090 |
Why?
|
| Monocytes | 1 | 2020 | 2595 | 0.090 |
Why?
|
| Time Factors | 7 | 2018 | 40065 | 0.090 |
Why?
|
| Feasibility Studies | 1 | 2022 | 5302 | 0.090 |
Why?
|
| Ultrasonography | 3 | 2016 | 5993 | 0.090 |
Why?
|
| Hematocrit | 1 | 2012 | 621 | 0.090 |
Why?
|
| Radiography | 3 | 2010 | 6919 | 0.090 |
Why?
|
| Fatal Outcome | 3 | 2004 | 1831 | 0.090 |
Why?
|
| Antiviral Agents | 1 | 2003 | 3050 | 0.090 |
Why?
|
| Muscle Proteins | 2 | 2014 | 1158 | 0.090 |
Why?
|
| Spinal Fractures | 1 | 2017 | 703 | 0.090 |
Why?
|
| Magnetic Resonance Angiography | 3 | 2002 | 1426 | 0.090 |
Why?
|
| Anti-Bacterial Agents | 3 | 2006 | 7478 | 0.090 |
Why?
|
| Hand Strength | 3 | 2022 | 462 | 0.090 |
Why?
|
| Drug Prescriptions | 1 | 2019 | 1662 | 0.080 |
Why?
|
| Kidney Failure, Chronic | 3 | 2009 | 2495 | 0.080 |
Why?
|
| Longitudinal Studies | 4 | 2021 | 14751 | 0.080 |
Why?
|
| Memory Disorders | 1 | 2017 | 1194 | 0.080 |
Why?
|
| Suicide | 1 | 2021 | 1604 | 0.080 |
Why?
|
| Estrogen Antagonists | 1 | 2010 | 150 | 0.080 |
Why?
|
| Aorta, Thoracic | 1 | 2016 | 1103 | 0.080 |
Why?
|
| Diabetes Mellitus, Type 1 | 2 | 2003 | 3446 | 0.080 |
Why?
|
| Hypothalamo-Hypophyseal System | 1 | 2013 | 697 | 0.080 |
Why?
|
| Delayed-Action Preparations | 2 | 2010 | 967 | 0.080 |
Why?
|
| Carcinoma, Renal Cell | 1 | 2004 | 3181 | 0.080 |
Why?
|
| Muscle Weakness | 1 | 2012 | 413 | 0.080 |
Why?
|
| Animals | 8 | 2022 | 168764 | 0.080 |
Why?
|
| Anxiety | 2 | 2021 | 4671 | 0.080 |
Why?
|
| Gonadotropins | 1 | 2010 | 240 | 0.080 |
Why?
|
| Cardiomyopathies | 1 | 2001 | 2067 | 0.080 |
Why?
|
| Cognition Disorders | 2 | 2013 | 3967 | 0.080 |
Why?
|
| Hip Fractures | 1 | 2017 | 997 | 0.080 |
Why?
|
| Brain Neoplasms | 1 | 2010 | 9071 | 0.080 |
Why?
|
| Multicenter Studies as Topic | 2 | 2015 | 1731 | 0.080 |
Why?
|
| Early Diagnosis | 1 | 2013 | 1187 | 0.080 |
Why?
|
| Ovarian Neoplasms | 1 | 2005 | 4900 | 0.080 |
Why?
|
| Nutritional Status | 1 | 2017 | 1620 | 0.070 |
Why?
|
| Coronary Artery Disease | 3 | 2017 | 6544 | 0.070 |
Why?
|
| Antimicrobial Cationic Peptides | 1 | 2010 | 348 | 0.070 |
Why?
|
| Primary Health Care | 2 | 2020 | 4736 | 0.070 |
Why?
|
| Acne Vulgaris | 2 | 2004 | 352 | 0.070 |
Why?
|
| Adolescent | 6 | 2021 | 88835 | 0.070 |
Why?
|
| Syndrome | 2 | 2004 | 3271 | 0.070 |
Why?
|
| Neutrophils | 1 | 2020 | 3776 | 0.070 |
Why?
|
| Androstane-3,17-diol | 1 | 2007 | 20 | 0.070 |
Why?
|
| Kidney Neoplasms | 1 | 2004 | 4274 | 0.070 |
Why?
|
| Nutrition Surveys | 2 | 2012 | 1741 | 0.070 |
Why?
|
| Anemia, Aplastic | 1 | 2009 | 232 | 0.070 |
Why?
|
| Menopause | 1 | 2015 | 1659 | 0.070 |
Why?
|
| Pain Measurement | 1 | 2017 | 3561 | 0.070 |
Why?
|
| Hirsutism | 2 | 2004 | 66 | 0.070 |
Why?
|
| Chemistry, Pharmaceutical | 1 | 2007 | 272 | 0.070 |
Why?
|
| Cadmium | 1 | 2008 | 218 | 0.070 |
Why?
|
| Chronic Disease | 1 | 2001 | 9347 | 0.070 |
Why?
|
| Enzyme Inhibitors | 1 | 2017 | 3715 | 0.070 |
Why?
|
| Pilot Projects | 2 | 2010 | 8733 | 0.070 |
Why?
|
| Fatty Liver | 1 | 2013 | 807 | 0.070 |
Why?
|
| Age Factors | 7 | 2021 | 18380 | 0.060 |
Why?
|
| Health Surveys | 3 | 2011 | 4056 | 0.060 |
Why?
|
| Reference Values | 4 | 2017 | 4908 | 0.060 |
Why?
|
| Self Report | 1 | 2017 | 3770 | 0.060 |
Why?
|
| Hydrocortisone | 4 | 2006 | 1827 | 0.060 |
Why?
|
| Waist-Hip Ratio | 1 | 2007 | 520 | 0.060 |
Why?
|
| Drug Administration Schedule | 2 | 2010 | 4850 | 0.060 |
Why?
|
| Wounds and Injuries | 1 | 2018 | 2511 | 0.060 |
Why?
|
| United States | 8 | 2024 | 72903 | 0.060 |
Why?
|
| HIV Infections | 2 | 2022 | 17533 | 0.060 |
Why?
|
| Bone Marrow | 2 | 2009 | 2921 | 0.060 |
Why?
|
| Image Interpretation, Computer-Assisted | 1 | 2018 | 3356 | 0.060 |
Why?
|
| Body Weight | 2 | 2014 | 4622 | 0.060 |
Why?
|
| Sleep Apnea, Obstructive | 1 | 2018 | 1896 | 0.060 |
Why?
|
| Liver Neoplasms | 1 | 2000 | 4353 | 0.060 |
Why?
|
| Palpation | 1 | 2004 | 166 | 0.060 |
Why?
|
| Erythrocytes | 2 | 2015 | 2395 | 0.060 |
Why?
|
| Prevalence | 6 | 2012 | 15842 | 0.060 |
Why?
|
| Postoperative Complications | 1 | 2006 | 15747 | 0.060 |
Why?
|
| Disabled Persons | 1 | 2014 | 1208 | 0.060 |
Why?
|
| Delivery of Health Care | 1 | 2002 | 5370 | 0.050 |
Why?
|
| Gene Expression | 1 | 2016 | 7584 | 0.050 |
Why?
|
| Weight Gain | 1 | 2014 | 2355 | 0.050 |
Why?
|
| Adrenalectomy | 1 | 2006 | 344 | 0.050 |
Why?
|
| Proto-Oncogene Proteins c-raf | 1 | 2004 | 206 | 0.050 |
Why?
|
| Blood Vessels | 1 | 2009 | 1113 | 0.050 |
Why?
|
| Natriuretic Peptide, Brain | 1 | 2012 | 1736 | 0.050 |
Why?
|
| Atenolol | 1 | 2003 | 99 | 0.050 |
Why?
|
| Triglycerides | 2 | 2002 | 2441 | 0.050 |
Why?
|
| Transdermal Patch | 1 | 2023 | 51 | 0.050 |
Why?
|
| Biopsy, Needle | 2 | 2006 | 1628 | 0.050 |
Why?
|
| Endothelium, Vascular | 1 | 2015 | 4427 | 0.050 |
Why?
|
| Diabetes Insipidus | 1 | 2003 | 143 | 0.050 |
Why?
|
| Overweight | 1 | 2014 | 2444 | 0.050 |
Why?
|
| Medroxyprogesterone | 1 | 2002 | 33 | 0.050 |
Why?
|
| Immunoglobulins, Thyroid-Stimulating | 1 | 2002 | 35 | 0.050 |
Why?
|
| Propylthiouracil | 1 | 2002 | 68 | 0.050 |
Why?
|
| Mass Spectrometry | 1 | 2010 | 2194 | 0.050 |
Why?
|
| Drug Design | 1 | 2007 | 1042 | 0.050 |
Why?
|
| Heart Rate | 1 | 2014 | 4204 | 0.050 |
Why?
|
| Thyrotropin-Releasing Hormone | 1 | 2002 | 139 | 0.050 |
Why?
|
| Scrotum | 1 | 2003 | 115 | 0.050 |
Why?
|
| Calcium | 1 | 2015 | 5767 | 0.050 |
Why?
|
| Multiple Sclerosis, Chronic Progressive | 1 | 2004 | 253 | 0.050 |
Why?
|
| Follow-Up Studies | 6 | 2019 | 39193 | 0.050 |
Why?
|
| Ovary | 1 | 2006 | 956 | 0.050 |
Why?
|
| Analysis of Variance | 3 | 2010 | 6203 | 0.050 |
Why?
|
| History, 20th Century | 1 | 2010 | 2761 | 0.050 |
Why?
|
| Sex Factors | 4 | 2021 | 10603 | 0.050 |
Why?
|
| Multiple Myeloma | 1 | 1999 | 5197 | 0.050 |
Why?
|
| Research Design | 1 | 2017 | 6209 | 0.050 |
Why?
|
| Biopsy, Fine-Needle | 2 | 2004 | 1133 | 0.050 |
Why?
|
| Thyroid Function Tests | 1 | 2002 | 293 | 0.050 |
Why?
|
| Logistic Models | 3 | 2012 | 13266 | 0.050 |
Why?
|
| Geriatric Assessment | 2 | 2020 | 1429 | 0.050 |
Why?
|
| Liver Cirrhosis, Alcoholic | 1 | 2001 | 64 | 0.040 |
Why?
|
| Pakistan | 1 | 2002 | 300 | 0.040 |
Why?
|
| Europe | 1 | 2007 | 3423 | 0.040 |
Why?
|
| Marfan Syndrome | 1 | 2002 | 237 | 0.040 |
Why?
|
| Pituitary Function Tests | 1 | 2000 | 24 | 0.040 |
Why?
|
| Iron | 1 | 2009 | 1816 | 0.040 |
Why?
|
| Hyperparathyroidism, Secondary | 1 | 2001 | 123 | 0.040 |
Why?
|
| beta-Thalassemia | 1 | 2003 | 233 | 0.040 |
Why?
|
| Renal Artery | 1 | 2002 | 345 | 0.040 |
Why?
|
| Technetium | 1 | 2000 | 326 | 0.040 |
Why?
|
| Cardiopulmonary Bypass | 1 | 2005 | 1090 | 0.040 |
Why?
|
| Nicotinic Acids | 1 | 2000 | 33 | 0.040 |
Why?
|
| Adrenal Cortex | 1 | 2000 | 134 | 0.040 |
Why?
|
| Diabetes Mellitus, Type 2 | 2 | 2023 | 12240 | 0.040 |
Why?
|
| Aspergillus fumigatus | 1 | 2001 | 158 | 0.040 |
Why?
|
| Lung | 1 | 2018 | 10033 | 0.040 |
Why?
|
| Pain | 1 | 2015 | 5077 | 0.040 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2010 | 6499 | 0.040 |
Why?
|
| Portasystemic Shunt, Transjugular Intrahepatic | 1 | 2001 | 95 | 0.040 |
Why?
|
| Lovastatin | 1 | 2000 | 114 | 0.040 |
Why?
|
| Coronary Artery Bypass | 2 | 2005 | 2186 | 0.040 |
Why?
|
| Multiple Sclerosis, Relapsing-Remitting | 1 | 2004 | 550 | 0.040 |
Why?
|
| Angioplasty | 1 | 2002 | 352 | 0.040 |
Why?
|
| Alendronate | 1 | 2000 | 174 | 0.040 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 1 | 2006 | 1514 | 0.040 |
Why?
|
| Aspergillosis | 1 | 2001 | 242 | 0.040 |
Why?
|
| Biological Transport | 1 | 2003 | 2081 | 0.040 |
Why?
|
| Adrenal Cortex Neoplasms | 1 | 2000 | 161 | 0.040 |
Why?
|
| Collagen Type I | 1 | 2002 | 615 | 0.040 |
Why?
|
| Aphasia | 1 | 2000 | 191 | 0.040 |
Why?
|
| Cushing Syndrome | 1 | 2000 | 241 | 0.040 |
Why?
|
| Neoplasms | 1 | 2007 | 22340 | 0.040 |
Why?
|
| Biopsy | 2 | 2000 | 6763 | 0.040 |
Why?
|
| Adrenocorticotropic Hormone | 1 | 2000 | 616 | 0.040 |
Why?
|
| National Health Programs | 1 | 2002 | 443 | 0.040 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2017 | 16047 | 0.040 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2006 | 3537 | 0.040 |
Why?
|
| Lipoproteins, HDL | 1 | 2002 | 674 | 0.040 |
Why?
|
| Bone Diseases, Metabolic | 2 | 2014 | 407 | 0.040 |
Why?
|
| Recurrence | 2 | 2001 | 8501 | 0.040 |
Why?
|
| Lung Volume Measurements | 1 | 2018 | 381 | 0.040 |
Why?
|
| HIV Seropositivity | 1 | 2003 | 961 | 0.030 |
Why?
|
| Hemophilia A | 1 | 2000 | 357 | 0.030 |
Why?
|
| Adverse Drug Reaction Reporting Systems | 1 | 2021 | 497 | 0.030 |
Why?
|
| Cysts | 1 | 2002 | 684 | 0.030 |
Why?
|
| Prostatic Hyperplasia | 1 | 2021 | 515 | 0.030 |
Why?
|
| Survival Rate | 2 | 2011 | 12795 | 0.030 |
Why?
|
| Ethanol | 1 | 2002 | 1323 | 0.030 |
Why?
|
| Dehydroepiandrosterone Sulfate | 2 | 2007 | 238 | 0.030 |
Why?
|
| Intention to Treat Analysis | 1 | 2017 | 416 | 0.030 |
Why?
|
| Incidence | 3 | 2020 | 21480 | 0.030 |
Why?
|
| Proto-Oncogene Proteins B-raf | 1 | 2005 | 2054 | 0.030 |
Why?
|
| Diphosphonates | 1 | 2000 | 625 | 0.030 |
Why?
|
| Focus Groups | 1 | 2002 | 1459 | 0.030 |
Why?
|
| Aromatase | 1 | 2015 | 147 | 0.030 |
Why?
|
| Kinetics | 1 | 2003 | 6274 | 0.030 |
Why?
|
| Hepacivirus | 1 | 2022 | 1343 | 0.030 |
Why?
|
| Foreign Bodies | 1 | 1999 | 402 | 0.030 |
Why?
|
| Self-Assessment | 1 | 2017 | 400 | 0.030 |
Why?
|
| Osteoblasts | 1 | 2000 | 1143 | 0.030 |
Why?
|
| Life Style | 2 | 2012 | 3926 | 0.030 |
Why?
|
| Tosyl Compounds | 1 | 2015 | 115 | 0.030 |
Why?
|
| Long-Term Care | 1 | 2019 | 629 | 0.030 |
Why?
|
| Endometrial Neoplasms | 1 | 2004 | 1378 | 0.030 |
Why?
|
| Health Care Surveys | 1 | 2002 | 2424 | 0.030 |
Why?
|
| SEER Program | 1 | 2019 | 1446 | 0.030 |
Why?
|
| Predictive Value of Tests | 2 | 2007 | 15398 | 0.030 |
Why?
|
| Models, Biological | 2 | 2008 | 9443 | 0.030 |
Why?
|
| Women's Health | 1 | 2004 | 2084 | 0.030 |
Why?
|
| Goserelin | 1 | 2014 | 126 | 0.030 |
Why?
|
| Ultrasonography, Interventional | 1 | 2002 | 1531 | 0.030 |
Why?
|
| Prosthesis Failure | 1 | 1999 | 1191 | 0.030 |
Why?
|
| Interviews as Topic | 2 | 2015 | 2739 | 0.030 |
Why?
|
| Combined Modality Therapy | 1 | 2006 | 8529 | 0.030 |
Why?
|
| Collagen | 1 | 2002 | 2618 | 0.030 |
Why?
|
| Gynecomastia | 1 | 2014 | 87 | 0.030 |
Why?
|
| Injections | 2 | 2010 | 840 | 0.030 |
Why?
|
| Drug Therapy, Combination | 2 | 2015 | 6309 | 0.030 |
Why?
|
| Neoplasm Invasiveness | 1 | 2002 | 3602 | 0.030 |
Why?
|
| Sample Size | 1 | 2017 | 845 | 0.030 |
Why?
|
| Sensitivity and Specificity | 2 | 2006 | 14652 | 0.030 |
Why?
|
| Prognosis | 4 | 2019 | 29922 | 0.030 |
Why?
|
| Brachial Artery | 1 | 2015 | 375 | 0.030 |
Why?
|
| Recombinant Proteins | 1 | 2003 | 6493 | 0.030 |
Why?
|
| Program Evaluation | 1 | 2002 | 2499 | 0.030 |
Why?
|
| Guidelines as Topic | 1 | 2000 | 1394 | 0.030 |
Why?
|
| Cholesterol, HDL | 1 | 2000 | 1811 | 0.030 |
Why?
|
| Hypoglycemic Agents | 1 | 2006 | 3110 | 0.030 |
Why?
|
| Radioimmunoassay | 1 | 2013 | 860 | 0.030 |
Why?
|
| Antiretroviral Therapy, Highly Active | 1 | 2021 | 1899 | 0.030 |
Why?
|
| Mass Screening | 1 | 2008 | 5446 | 0.030 |
Why?
|
| Headache | 1 | 2000 | 1259 | 0.030 |
Why?
|
| Prostheses and Implants | 1 | 1999 | 1273 | 0.020 |
Why?
|
| Colonoscopy | 1 | 2000 | 1406 | 0.020 |
Why?
|
| Immunohistochemistry | 1 | 2006 | 11022 | 0.020 |
Why?
|
| Coitus | 1 | 2012 | 133 | 0.020 |
Why?
|
| Anilides | 1 | 2015 | 415 | 0.020 |
Why?
|
| Regression Analysis | 2 | 2014 | 6322 | 0.020 |
Why?
|
| Hematopoiesis | 1 | 2001 | 2058 | 0.020 |
Why?
|
| Hot Flashes | 1 | 2014 | 330 | 0.020 |
Why?
|
| Hospitalization | 2 | 2022 | 10808 | 0.020 |
Why?
|
| DNA Methylation | 1 | 2005 | 4424 | 0.020 |
Why?
|
| Anti-Inflammatory Agents | 1 | 2000 | 1808 | 0.020 |
Why?
|
| Statistics as Topic | 1 | 2017 | 2352 | 0.020 |
Why?
|
| Intracranial Aneurysm | 1 | 2000 | 1272 | 0.020 |
Why?
|
| Observer Variation | 1 | 2017 | 2615 | 0.020 |
Why?
|
| Mental Recall | 1 | 2017 | 1218 | 0.020 |
Why?
|
| Peptides | 1 | 2002 | 4331 | 0.020 |
Why?
|
| Stents | 1 | 2002 | 3213 | 0.020 |
Why?
|
| Kidney Diseases | 1 | 2000 | 2098 | 0.020 |
Why?
|
| Intestinal Mucosa | 1 | 2000 | 3046 | 0.020 |
Why?
|
| Gait | 1 | 2014 | 820 | 0.020 |
Why?
|
| Odds Ratio | 2 | 2012 | 9649 | 0.020 |
Why?
|
| Androstanes | 1 | 2008 | 20 | 0.020 |
Why?
|
| Linear Models | 2 | 2010 | 5876 | 0.020 |
Why?
|
| Arousal | 1 | 2014 | 1171 | 0.020 |
Why?
|
| Mental Health Services | 1 | 2019 | 1723 | 0.020 |
Why?
|
| Multivariate Analysis | 2 | 2014 | 12056 | 0.020 |
Why?
|
| Algorithms | 1 | 2008 | 14071 | 0.020 |
Why?
|
| Interleukin 1 Receptor Antagonist Protein | 1 | 2008 | 297 | 0.020 |
Why?
|
| Memory | 1 | 2017 | 2190 | 0.020 |
Why?
|
| Heart Ventricles | 1 | 1999 | 3832 | 0.020 |
Why?
|
| Health | 1 | 2010 | 397 | 0.020 |
Why?
|
| Confidence Intervals | 1 | 2012 | 2910 | 0.020 |
Why?
|
| Echocardiography | 1 | 1999 | 5045 | 0.020 |
Why?
|
| Task Performance and Analysis | 1 | 2010 | 770 | 0.020 |
Why?
|
| Disability Evaluation | 1 | 2014 | 1820 | 0.020 |
Why?
|
| Chromatography, High Pressure Liquid | 1 | 2010 | 1526 | 0.020 |
Why?
|
| Retrospective Studies | 4 | 2019 | 81514 | 0.020 |
Why?
|
| Evidence-Based Medicine | 1 | 2018 | 3685 | 0.020 |
Why?
|
| Tumor Necrosis Factor-alpha | 2 | 2008 | 4348 | 0.020 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2019 | 3230 | 0.020 |
Why?
|
| Sulfites | 1 | 2005 | 83 | 0.020 |
Why?
|
| Biological Availability | 1 | 2006 | 385 | 0.020 |
Why?
|
| Health Status Disparities | 1 | 2017 | 1880 | 0.020 |
Why?
|
| Serum Albumin | 1 | 2008 | 675 | 0.020 |
Why?
|
| Postural Balance | 1 | 2010 | 637 | 0.020 |
Why?
|
| Health Status Indicators | 1 | 2010 | 966 | 0.020 |
Why?
|
| Bone and Bones | 1 | 2015 | 2554 | 0.020 |
Why?
|
| Coronary Angiography | 1 | 2017 | 4493 | 0.020 |
Why?
|
| Severity of Illness Index | 1 | 2003 | 15880 | 0.010 |
Why?
|
| Neoplasm Staging | 1 | 2019 | 11206 | 0.010 |
Why?
|
| Dehydroepiandrosterone | 1 | 2005 | 248 | 0.010 |
Why?
|
| Body Size | 1 | 2007 | 459 | 0.010 |
Why?
|
| Colorimetry | 1 | 2004 | 148 | 0.010 |
Why?
|
| Smoking | 2 | 2012 | 9081 | 0.010 |
Why?
|
| Down-Regulation | 1 | 2010 | 2927 | 0.010 |
Why?
|
| Creatinine | 1 | 2008 | 1915 | 0.010 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2023 | 11868 | 0.010 |
Why?
|
| Random Allocation | 1 | 2007 | 2395 | 0.010 |
Why?
|
| Fasting | 1 | 2008 | 1606 | 0.010 |
Why?
|
| Reproducibility of Results | 1 | 2020 | 20124 | 0.010 |
Why?
|
| Interleukin-1 | 1 | 2005 | 1243 | 0.010 |
Why?
|
| Medicare | 1 | 2019 | 6823 | 0.010 |
Why?
|
| DNA Primers | 1 | 2005 | 2825 | 0.010 |
Why?
|
| Mutation | 1 | 2005 | 30198 | 0.010 |
Why?
|
| Glomerular Filtration Rate | 1 | 2008 | 2233 | 0.010 |
Why?
|
| Alcohol Drinking | 1 | 2012 | 4040 | 0.010 |
Why?
|
| Boston | 1 | 2012 | 9338 | 0.010 |
Why?
|
| Point Mutation | 1 | 2004 | 1590 | 0.010 |
Why?
|
| Corticotropin-Releasing Hormone | 1 | 2000 | 361 | 0.010 |
Why?
|
| Leptin | 1 | 2006 | 1596 | 0.010 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2005 | 4562 | 0.010 |
Why?
|
| Lung Neoplasms | 1 | 2002 | 13451 | 0.010 |
Why?
|
| Neoplasm Recurrence, Local | 2 | 2005 | 9373 | 0.010 |
Why?
|
| Breast Neoplasms | 1 | 2004 | 21056 | 0.010 |
Why?
|
| Mice, Inbred C57BL | 1 | 2015 | 22332 | 0.010 |
Why?
|
| Mortality | 1 | 2007 | 2904 | 0.010 |
Why?
|
| Mice | 2 | 2015 | 81819 | 0.010 |
Why?
|
| Dexamethasone | 1 | 2000 | 1963 | 0.010 |
Why?
|
| DNA | 1 | 2005 | 7202 | 0.010 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2005 | 18071 | 0.000 |
Why?
|